2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Epigenetics
  4. Aurora Kinase

Aurora Kinase

Aurora Kinase

Related Products

PDF 0.27 MB

The Aurora kinases comprise a family of evolutionary conserved serine/threonine kinases (Aurora-A, Aurora-B, and Aurora-C). Aurora kinases control multiple events during cell cycle progression and are essential for mitotic and meiotic bipolar spindle assembly and function.

Aurora-A, Aurora-B, and Aurora-C share a highly conserved kinase domain but have quite different subcellular localizations and functions during mitosis. Aurora-A mostly controls centrosome maturation and bipolar spindle assembly, while Aurora-B and Aurora-C are required for condensation, attachment to kinetochores, and alignment of chromosomes during (pro-)metaphase and cytokinesis. In human tumors, all Aurora kinase members play oncogenic roles related to their mitotic activity and promote cancer cell survival and proliferation. Inhibitors targeting Aurora kinases have attracted attention in cancer research.

Aurora Kinase Isoform Specific Products:

Aurora Kinase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-161407
    AURKA-IN-1
    		Inhibitor
    AURKA-IN-1 (compound 9) is an cell-active covalent AURKA inhibitor. AURKA-IN-1 is a lysine-reactive activity probe.
    AURKA-IN-1
  • HY-RS01266
    AURKA Human Pre-designed siRNA Set A
    		Inhibitor

    AURKA Human Pre-designed siRNA Set A contains three designed siRNAs for AURKA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    AURKA Human Pre-designed siRNA Set A
  • HY-149694
    Aurora kinase inhibitor-12
    		Inhibitor
    Aurora kinase inhibitor-12 (Compound 1a ) is the inhibitor of aurora kinase which is a key enzyme that is implicated in tumor growth.
    Aurora kinase inhibitor-12
  • HY-115932
    Aurora kinase-IN-1
    		Inhibitor
    Aurora kinase-IN-1 (Compound 9) is a potent inhibitor of aurora kinase. Aurora kinase-IN-1 upregulates the expression of G1 cell cycle inhibitory proteins including p21 and p27, and G1 progressive cyclin D1, and downregulates G1-to-S progressive cyclins, resulting in cell cycle arrest at the G1/S boundary. Aurora kinase-IN-1 also induces apoptosis. Aurora kinase-IN-1 is a lead compound for chemotherapeutic agents.
    Aurora kinase-IN-1
  • HY-125158A
    (E/Z)-HOI-07
    		Inhibitor
    (E/Z)-HOI-07 is a potent and selective Aurora B inhibitor. HOI-07 has antitumor activity.
    (E/Z)-HOI-07
  • HY-146037
    Aurora A inhibitor 2
    		Inhibitor
    Aurora A inhibitor 2 (Compound 16h) is a potent Aurora A kinase inhibitor with an IC50 of 21.94 nM. Aurora A inhibitor 2 induces caspase-dependent apoptosis in MDA-MB-231 cells.
    Aurora A inhibitor 2
  • HY-70044G
    GSK-1070916 (GMP)
    		Inhibitor
    GSK-1070916 (GMP) is GSK-1070916 (HY-70044) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with Kis of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.
    GSK-1070916 (GMP)
  • HY-RS01275
    AURKC Rat Pre-designed siRNA Set A
    		Inhibitor

    AURKC Rat Pre-designed siRNA Set A contains three designed siRNAs for AURKC gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    AURKC Rat Pre-designed siRNA Set A
  • HY-160691
    GW814408X
    		Inhibitor
    GW814408X is a kinase chemical genome group (KCGS) compound that inhibits the AURKC kinase involved in cell cycle progression, checkpoint regulation, and cell division. GW814408X exhibits cell line-dependent toxicity, e.g., cytotoxic effects on HeLa cells. GW814408X acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential implications for Fluc reporter assays.
    GW814408X
  • HY-175830
    PROTAC AURKA degrader 1
    		Degrader
    PROTAC AURKA degrader 1 (Compound A16 + X7) is a Aurora kinase A (AURKA) PROTAC degrader. PROTAC AURKA degrader 1 can be used for cancers research. Pink: AURKA ligand (HY-175827); Blue: CRBN ligase ligand (HY-W867704); Black: linker (HY-132208)
    PROTAC AURKA degrader 1
  • HY-RS01273
    AURKC Human Pre-designed siRNA Set A
    		Inhibitor

    AURKC Human Pre-designed siRNA Set A contains three designed siRNAs for AURKC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    AURKC Human Pre-designed siRNA Set A
  • HY-162837
    AURKA against 1
    		Inhibitor
    AURKA against 1 is an inhibitor of AURKA (IC50 less than 0.5 nM), targeting endogenous lysine (K162) acetylation, and has anti-proliferation activity against tumor cells. AURKA against 1 induces K162 acetylation, and the kinase activity of AURKA is reversibly restored in HCT116 cells transfected with SIRT3.
    AURKA against 1
  • HY-108919
    CG-1521
    		Inhibitor
    CG-1521 is a histone deacetylase (HDAC) inhibitor that stabilizes Ac-Lys373 P53, increases P21 levels and HDAC2 degradation. CG-1521 can inhibit proliferation, induce cell cycle arrest and apoptosis. CG-1521 promotes Bax translocation to the mitochondria and cleavage. CG-1521 downregulates KIF4, Aurora B and Nek2 protein expression and DNA synthesis. CG-1521 can be used for the research of prostate cancer and inflammatory breast cancer.
    CG-1521
  • HY-113894
    Retreversine
    Retreversine is an inactive control for Reversine. Reversine is a novel class of ATP-competitive Aurora kinase inhibitor.
    Retreversine
  • HY-179640
    SK4454
    		Degrader
    SK4454 is a selective AURKA PROTAC degrader degrading AURKA with IC50 = 8 nM. MYCN levels in MYCN-amplified neuroblastoma cells and limited by MDR1-mediated efflux. SK4454 efficiently reduced AURKA levels in vivo. SK4454 can be used for neuroblastoma research.
    SK4454
  • HY-165369
    IBPR002
    		Inhibitor
    IBPR002 is an inhibitor of Aurora kinase A and Aurora kinase B, with IC50 values of 41 nM and 17 nM, respectively. IBPR002 disrupts the nucleation and bundling of kinetochore microtubules, impairs the bipolarity of mitotic spindles, and promotes the binding of non-phosphorylated hepatoma up-regulated protein (HURP) to microtubules derived from the mother centrosome. IBPR002 reduces tumorigenesis levels in a colorectal cancer xenograft model using athymic nude mice. IBPR002 is applicable for research related to colorectal cancer.
    IBPR002
  • HY-114526
    INH-13
    		Inhibitor
    INH-13 is a Aurora inhibitor. INH-13 is applicable for cancer research.
    INH-13
  • HY-183767
    Aurora kinase/ALK-IN-1
    		Inhibitor
    Aurora kinase/ALK-IN-1 is a dual Aurora A kinase and ALK inhibitor with IC50 values of 0.296 μM and 0.332 μM, respectively. Aurora kinase/ALK-IN-1 induces G2/M cell cycle arrest, triggers mitochondrial apoptosis, elevates intracellular reactive oxygen species (ROS) levels, and inhibits ALDH1 activity. Aurora kinase/ALK-IN-1 demonstrates cytotoxicity and tumor selectivity. Aurora kinase/ALK-IN-1 can be used for the research of anaplastic large cell lymphoma.
    Aurora kinase/ALK-IN-1
  • HY-119951
    AKI-001
    		Inhibitor
    AKI-001 is an prototype pentacyclic inhibitor of aurora kinase with cellular potency of IC50 of less than 100 nM. AKI-001 shows low nanomolar potency against Aurora A and Aurora B enzymes.
    AKI-001
  • HY-181626
    NN-01-195
    		Inhibitor
    NN-01-195 is a HSP90 and AURKA inhibitor. NN-01-195 binds tightly to and inhibits AURKA and HSP90, with an IC50 of 3.1 nM against AURKA and an IC50 of 8.7 nM against HSP90α. NN-01-195 induces mitotic arrest and spindle abnormality in tumor cells, and triggers cell apoptosis. NN-01-195 can be used in the research of solid tumors.
    NN-01-195
Cat. No. Product Name / Synonyms Application Reactivity
Aurora Kinase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.